The global intravenous immunoglobulin market is likely to witness considerable growth driven by recent molecular advancements. According to a report published by Fortune Business Insights, titled “Intravenous Immunoglobulin Market Size, Share & Industry Analysis By Indication (Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barré Syndrome (GBS), Immune Thrombocytopenic Purpura (ITP), Multifocal Motor Neuropathy (MMN)), Form (Liquid, Lyophilized), End User (Hospitals, Clinics, Homecare) & Regional Forecast, 2018 – 2025,” the was valued at USD 9,787.6 Million in 2017 and is projected to reach USD 15,789.1 Million by 2025 exhibiting a CAGR of 6.2% in the forecast period (2018-2025).
Browse Complete Report Details: https://www.fortunebusinessinsights.com/industry-reports/intravenou...
Intravenous immunoglobulin is a blood product prepared from the serum of a particular range. It is mostly used for treatment of patients with major antibody deficiencies. They are categorized as glycoprotein molecules manufactured by plasma or white blood cells (WBC). These products are used to enhance the immune system by binding specific antigens such as bacteria and virus. As a result, they cater to patients with a weaker or exposed immune system. Intravenous immunoglobulins are the type of drugs that are directly administered to the veins through syringes. The intravenous route is preferred n critical and bed-ridden patients, that have a lesser effect through oral or other modes. The proven efficiency of these drugs will lead to high product adoption across the world.
The report encompasses several factors that have contributed to market growth in recent years. It provides a summary of the latest intravenous immunoglobulin market trends. Key market aspects such as competitive landscape, areas witnessing highest product adoption and demand, and major companies are discussed in detail. Additionally, the report highlights leading segments of the market and gauges their impact on the global market.
Growing Regulatory Approvals Will Open the Doors for Rapid Growth
The high demand for immunoglobulins has given rise to an increase in the overall investments in the development of these products across the world. Increasing investments have led to a subsequent rise in the number of clinical trials. Encouraged by successful clinical trials and excellent results, the regulatory bodies are actively approving several new products. Increasing regulatory clearances will have a direct impact on the growth of the global market. A few of the major drug approvals of recent times are summarized below.
AMDA Biologics’ Bivigam was cleared by the Food and Drug Administration in 2019. The company is likely to begin commercialization and sale of its product in the coming years.
Asceniv, another immunoglobulin by proposed by ADMA, was approved by the FDA. The product was manufactured, with focus on severe immunodeficiency cases.